Physician profile
Teri Greer
NPI 1891195764
$3,109.25
in general payments reported to CMS, 2019-2025
24 companies · $404 in 2025
The $404 reported for 2025 was more than what 77% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $539 · 2023: $797 · 2024: $738 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.96 |
| Education | $201.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.98 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $382.78 | 2021-2025 | |
| Exeltis, USA INC. | $352.12 | 2021-2025 | Slynd, Twirla |
| Astellas Pharma US INC | $326.99 | 2023-2025 | Veozah, Myrbetriq |
| Millicent US INC | $294.34 | 2022-2025 | Intrarosa, Femring, Femlyv |
| Agile Therapeutics, INC. | $140.66 | 2021-2022 | |
| Channel Medsystems, INC. | $121.99 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.31 | 2021-2023 | |
| Novo Nordisk INC | $90.92 | 2024 | Wegovy |
| Mylan Pharmaceuticals INC. | $83.32 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $74.19 | 2023-2024 | Contrave, Nexlizet, Nexletol |
| Avion Pharmaceuticals | $73.26 | 2021-2023 | Balcoltra |
| Organon LLC | $71.84 | 2021-2024 | |
| Lilly USA, LLC | $52.24 | 2024 | Zepbound |
| Shield Therapeutics INC | $48.88 | 2023 | Accrufer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $47.22 | 2021-2024 | Paragard T 380a |
| Axonics, INC. | $42.68 | 2023 | Axonics |
| Ascend Therapeutics US, LLC | $37.05 | 2023-2024 | |
| Pfizer INC. | $30.96 | 2021-2024 | |
| Ibsa Pharma INC. | $27.41 | 2025 | Licart, Flector, Tirosint |
| Idorsia Pharmaceuticals US INC | $27.00 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $25.22 | 2023 | Gemtesa |
| Amgen INC. | $18.89 | 2021 | |
| Evofem Biosciences, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.